Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation.

Slides:

Advertisements

Similar presentations

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Advertisements

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Figure 1 Principle coordinates analysis plot for 127 Escherichia coli isolates from the SENTRY and Meropenem Yearly Susceptibility Test Information Collection.

Table 1 Characteristics of the 968 Women in the Study Group

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

From: Rotarix: A Rotavirus Vaccine for the World

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Table 1 Criteria for proven invasive fungal disease except for endemic mycoses. From: Revised Definitions of Invasive Fungal Disease from the European.

From: Postinfectious Irritable Bowel Syndrome

Figure 1 Adverse events after typhoid fever vaccination reported to the Vaccine Adverse Events Reporting System, by vaccination date and vaccine type,

Table 5 Sample format for results of Streptococcus pneumoniae isolate testing in a laboratory that routinely performs only oxacillin disk tests for penicillin.

Table 1 Baseline (before receipt of antiretroviral prophylaxis) characteristics of the pregnant women (transmitting or nontransmitting mothers included.

Figure 1 Annual per-capita consumption of all fermented milks and yogurt only in selected countries in Europe and North America [3, 4]. From: Probiotic.

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European.

G. Cornaglia, A. Lönnroth, M. Struelens

Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period J. Liñares, C. Ardanuy, R. Pallares, A.

Approach to diagnosis of infective endocarditis

Activity of quinupristin–dalfopristin in invasive isolates of Streptococcus pneumoniae from Italy A. Pantosti, F. D'Ambrosio, E. Bordi, A. Scotto d'Abusco,

Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America

P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys

Herpes zoster in non-hospitalized children

M.L. McMorrow, M. Aidoo, S.P. Kachur

Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era S. Nunes,

Necrotizing pneumonia caused by nanC-carrying serotypes is associated with pneumococcal haemolytic uraemic syndrome in children R.-P. Janapatla, M.-H.

Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in eight French counties J. Maugein, D. Guillemot, M.J. Dupont, T. Fosse,

Antimicrobial resistance of nasopharyngeal pneumococci from children from day-care centres and orphanages in Russia: results of a unique prospective multicentre.

Bernard Grenier Clinical Microbiology and Infection

Single-dose extended-release oral azithromycin vs

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program M.

Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients?

Serotypes, biotypes and antimicrobial susceptibilities of Haemophilus influenzae isolated from invasive disease in children in Casablanca N. Moustaoui,

Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era S. Nunes,

D.E. Low Clinical Microbiology and Infection

The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System M.E.A. de Kraker, V. Jarlier,

Viruses detected by systematic multiplex polymerase chain reaction in adults with suspected community-acquired pneumonia attending emergency departments.

Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European.

Carriage of resistant pneumococci by children in southern Israel and impact of conjugate vaccines on carriage Ron Dagan, Drora Fraser, Noga Givon, Pablo.

G. Höffken Clinical Microbiology and Infection

D. Esel, B. Sümerkan, S. Kocagöz Clinical Microbiology and Infection

Prevalence of Streptococcus pneumoniae isolates bearing macrolide resistance genes in association with integrase genes of conjugative transposons in Japan

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic.

Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin King A. , Bathgate.

Ecological effects on the oro- and nasopharyngeal microflora in children after treatment of acute otitis media with cefuroxime axetil or amoxycillin-clavulanate.

Recent developments in staphylococcal scalded skin syndrome

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

Community-acquired pneumonia: epidemiologic and clinical consideration

Changes in Streptococcus pneumoniae serotypes causing invasive disease with non- universal vaccination coverage of the seven-valent conjugate vaccine

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

G.M. Rossolini, E. Mantengoli Clinical Microbiology and Infection

Clinical Microbiology and Infection

Abstracts Clinical Microbiology and Infection

Modification of prescribers’ behavior: the Icelandic approach

O. Megged, A.M. Yinnon, D. Raveh, B. Rudensky, Y. Schlesinger

Presentation transcript:

Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation “Az” indicate the time of mass administration of azithromycin to all children 1–10 years of age as part of an ongoing project described elsewhere [15]. Shaded swab symbol, time nasopharyngeal swab obtained, questionnaire administered, and skin examination performed. “Study period” refers to the present study to determine the secondary effects of mass administration of azithromycin From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4):395-402. doi:10.1086/341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

Table 1 Demographic and clinical characteristics of children in 3 groups at baseline (day 0) in study of secondary effects of mass treatment with azithromycin From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4):395-402. doi:10.1086/341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

Table 2 Rates of nasopharyngeal carriage and antimicrobial resistance for Streptococcus pneumoniae isolates from children in study of secondary effects of mass treatment with azithromycin From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4):395-402. doi:10.1086/341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

Table 3 Proportions of children with impetigo (detected by skin examination) and symptoms of illness (reported during interview) on days 0 and 10 From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4):395-402. doi:10.1086/341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

Figure 2 Comparison of proportions of children with symptoms of gastrointestinal illness (reported during interview) and impetigo (detected by skin examination) at days 0, 10, and 180 after administration of azithromycin. NA, not applicable because no nasopharyngeal swabs were obtained at day 10. *P <.05 for comparison with day 0 From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4):395-402. doi:10.1086/341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America